Citic Securities: Maintain "buy" rating for Haitian Health (06078) with a target price of HKD 20.

According to the Wise Wealth APP, Zhongxin Securities released a research report stating that in the first half of 2025, Haige Medical (06078) had its performance under temporary pressure, but high-quality development is beginning to show results. The company's proportion of technical services continues to rise, and talent team construction is progressing steadily. In the first half of 2025, the company's new projects are progressing orderly, and it continues to develop innovative medical services. Referring to the valuation level of comparable companies, the company is given a 20x PE ratio for 2025, corresponding to a target price of 20 Hong Kong dollars in 2025, and maintains a "buy" rating.